drugset / Trial / NCT05406817
Study of Radiolabeled Revumenib in Adults With Acute Leukemia
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label study to evaluate the absorption, metabolism, and excretion (AME) of carbon-14 (\[14C\])-revumenib in participants with acute leukemia.
Timeline
- Start
- 2022-08-05
- Primary completion
- 2024-11-18
- Completion
- 2024-11-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Revumenib | Small molecule | — | Oral |